Recent studies highlight transformative genomic and molecular discoveries across oncology and beyond. Multi-omics investigations reveal T-cell exhaustion mechanisms and galectin-9 targets in chronic lymphocytic leukemia, while the transcription factor IRX3 emerges as a crucial regulator of adipocyte differentiation affecting fat cell precursor fate. NSD2 inhibitors demonstrate chromatin reprogramming effects with anti-cancer potential. Innovative diagnostics utilize CT radiomics to predict non-small cell lung cancer progression, and long non-coding RNAs modulate colorectal cancer gene expression. Collectively, these advances deepen understanding of tumor biology and open avenues for precision therapeutics.